<DOC>
	<DOCNO>NCT02259361</DOCNO>
	<brief_summary>This study evaluate effect sustained-release oral dalfampridine treatment upper limb deficit people multiple sclerosis ( MS ) . In double-blind randomized pilot study half participant dalfampridine , half receive placebo .</brief_summary>
	<brief_title>Efficacy Dalfampridine Upper Extremity Function Patients With MS</brief_title>
	<detailed_description>Dalfampridine ( ampyra ) , drug mechanism symptomatic management MS among block potassium channel demyelinate neuron , allow normal electrical conduction . Dalfampridine recently find associated improvement visual function , strength , ambulation , fatigue , endurance individual MS . Although medication widespread effect , influence upper extremity function never investigate double blind randomized case control study . Following fact disease course , approximately 3 4 multiple sclerosis patient encounter upper limb dysfunction primary objective study investigate efficacy sustained-release oral dalfampridine upper extremity function patient MS .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>1 . The patient must ability understand purpose risk study provide sign date informed consent authorize confidential health information examine accordance national local subject privacy regulation . 2 . The patient must diagnose clinically definite MS , time informed consent . 3 . The patient must 1870 year age , inclusive , time informed consent . 4 . The patient must score 50 90 upper limb Motricity Index test , time informed consent . This test evaluate strength three essential movement ( pinch grasp , elbow flexion shoulder abduction ) . The select score range criterion determine patient suffer moderate decline function ability upper limb . 1 . Onset multiple sclerosis exacerbation within 60 day screen . 2 . History seizures evidence epileptic form activity find screen electroencephalogram . 3 . Changes concomitant medication avoid relate change multiple sclerosis symptom study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>